Drug-induced liver injury (DILI) is an adverse reaction to drugs or other xenobiotics that
occurs either as a predictable event when an individual is exposed to toxic doses of some …

Drug-induced liver injury (DILI) is a patient-specific, temporal, multifactorial
pathophysiological process that cannot yet be recapitulated in a single in vitro model …

Drug-induced liver injury (DILI) can broadly be divided into predictable and dose dependent
such as acetaminophen (APAP) and unpredictable or idiosyncratic DILI (IDILI). Liver injury …

Immune checkpoint inhibitors (ICI s) block CTLA‐4, PD‐1 and PD‐L1, or other molecules
that control antitumour activities of lymphocytes. These products are associated with a broad …

Drug-induced liver injury (DILI) presents unique challenges for consumers, clinicians, and
regulators. It is the most common cause of acute liver failure in the US. It is also one of the …

Isoniazid (INH) remains a mainstay for the treatment of tuberculosis despite the fact that it
can cause liver failure. Previous mechanistic hypotheses have classified this type of drug …

Background & Aims We performed a genome-wide association study (GWAS) to identify
genetic risk factors for drug-induced liver injury (DILI) from licensed drugs without previously …

Idiosyncratic drug-induced liver injury (IDILI) remains a significant problem for patients and
drug development. The idiosyncratic nature of IDILI makes mechanistic studies difficult, and …

Immune checkpoint inhibitors (ICI) are being increasingly used to successfully treat several
types of cancer. However, due to their mode of action, these treatments are associated with …

Background: Drug-induced Liver Injury (DILI) is an important cause of acute liver failure
cases in the United States, and remains a common cause of withdrawal of drugs in both …